![]() Speakers included Kelly McNeil-Posey, director of health economics and outcomes research at Alexion and Sharon Williams, director of U.S. 3 It has also been shown to inhibit tissue factor pathway inhibitor activity, which increases thrombin generation and further promotes coagulation. andexanet alfa (Ondexxya) SMC ID: SMC2273 Indication: For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The panel discussion detailed an approved model structure developed with clinical guidance on the cost-effectiveness and budgetary impact of andexanet alfa on selected health outcomes and costs. Andexanet alfa is a recombinant modified human coagulation factor Xa protein that binds and sequesters apixaban and rivaroxaban, exerting a procoagulant effect. webinar “Andexanet alfa Budget Impact Model” originally broadcast on May 26 has been posted online. ![]() ![]() The DFW Hospital Council (DFWHC) and Alexion Pharmaceuticals, Inc. A full HTA is required to assess the clinical effectiveness and cost-effectiveness of andexanet alfa compared with the current standard of care. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |